NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations for molecular SARS-CoV-2 tests developed by DxTerity Diagnostics and Patients Choice Laboratories.
The DxTerity SARS-CoV-2 RT-PCR CE Test is an endpoint RT-PCR-based test followed by detection with capillary electrophoresis. It is designed to detect the virus' N, E, and ORF1ab genes in saliva specimens self-collected using Spectrum Solutions' SDNA-1000 Saliva Collection Device.